Cost-Effectiveness Analysis of Insulin Pump Therapy for Patients with Type 2 Diabetes Mellitus in the Perioperative Period

Na Li; Jiewei Huang; Peiru Zhou; Xueyan Liu; Xiaohua Lu; Qingling Chen; Yan Zhou

doi:doi:10.11648/j.ijde.20220703.15

| Peer-Reviewed

Cost-Effectiveness Analysis of Insulin Pump Therapy for Patients with Type 2 Diabetes Mellitus in the Perioperative Period

Na Li, Jiewei Huang, Peiru Zhou, Xueyan Liu, Xiaohua Lu, Qingling Chen, Yan Zhou

Published in International Journal of Diabetes and Endocrinology (Volume 7, Issue 3)

Received: 7 August 2022 Accepted: 21 August 2022 Published: 27 August 2022

Views: Downloads:

Download PDF

Share This Article

Twitter
Linked In
Facebook

Abstract

Objective: In recent years, insulin pump, as one of the effective glycemic control therapy in perioperative hyperglycemia patients, has been gradually applied and promoted in clinical type 2 diabetes patients, but there is a contradictory statements of whther it is ecomonical. To analyze the cost and effect of perioperative insulin pump treatment in patients with type 2 diabetes, this artical compared the cost-effectiveness of glucose control in the perioperative insulin pump treatment group (CSII group) with multiple daily subcutaneous insulin treatment group (MDI group) and subcutaneous insulin + oral hypoglycemic drug treatment group (subcutaneous + oral treatment group). Methods: This study is based on the cost-effectiveness analysis method, compared the difference in glucose-control treatment costs and treatment effect of the three perioperative glucose control schemes, and conducted the sensitivity analysis of the corresponding indicators. Results: The comparison of the basic data between the three patient groups was not significantly significant (P > 0.05), and it was comparable. The fastest in CSII was (3.52 ± 2.94) days, and the incidence of postoperative infection in CSII patients was basically the same as that in the subcutaneous + oral treatment group, with 12.9% and 12.5%, respectively. The savings in CSII, MDI and subcutaneous + oral treatment by 1d were 609.07, 343.83 and 311.25, respectively, much more in CSII than MDI and subcutaneous + oral treatment; reducing the postoperative infection rate by 1 percentage point was 166.20, 60.34 and 135.70, respectively, in CSII than MDI and subcutaneous + oral treatment. Comprehensive analysis shows that CSII has a good cost-effectiveness. The results of sensitivity analysis showed the credibility and stability of this study. Conclusions: Insulin pump treatment in perioperative type 2 diabetes patients is a cost-effectiveness treatment scheme, and it is very useful in perioperative type 2 diabetes patients.

Published in	International Journal of Diabetes and Endocrinology (Volume 7, Issue 3)
DOI	10.11648/j.ijde.20220703.15
Page(s)	70-76
Creative Commons	This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.
Copyright	Copyright © The Author(s), 2022. Published by Science Publishing Group

Keywords

Perioperative, Type 2 Diabetes, Insulin Pump, Cost-Effectiveness Analysis

References

[1]	Diabetes Branch of Chinese Medical Association. Chinese Guidelines for the Prevention and Treatment of Type 2 Diabetes (2020 edition). [J] Chinese Journal of Endocrinology and Metabolism, 2021, 37 (04): 311-398.
[2]	Idf diabetes atlas 9th edition. [EB/OL]. http://www.diabetesatlas.org/.2021-10-30/2019-12-10.
[3]	LF. M. Perioperative management of diabetes: translating evidence into practice. [J] Cleve Clin J Med, 2009, 76 (4): S53-S59.
[4]	Xiaoyu Chen, Jiewei Huang, Yanping Li, et al. Status and analysis of patients with perioperative insulin pump.[J] Chinese Electronic Journal of Obesity and Metabolic Diseases, 2020, 6 (1): 41-46.
[5]	Peiying Huang. Progress in blood glucose management in non-diabetic patients after surgery. [J] Chinese Journal of Clinicians (electronic edition). 2013, 7 (03): 1186-1188.
[6]	Shanks AM, Woodrum DT, Kumar SS, et al. Intraoperative hyperglycemia is independently associated with infectious complications after non-cardiac surgery. [J] BMC Anesthesiology, 2018, 18 (1): 90.
[7]	Alexiewicz JM, Kumar D, Smogorzewski M, et al. Polymorphonuclear Leukocytes in Non-Insulin-dependent Diabetes Mellitus: Abnormalities in Metabolism and Function. [J] Annals of Internal Medicine, 1995, 123 (12): 919-924.
[8]	Offodile AC, Chou H-Y, Lin JA-J, et al. Hyperglycemia and risk of adverse outcomes following microvascular reconstruction of oncologic head and neck defects. [J] Oral Oncology, 2018, 79: 15-19.
[9]	Jie Zhang. Current status of application and management of perioperative insulin pump in diabetic patients [J] Journal of Qilu Nursing. 2012, 18 (3): 48-49.
[10]	Min Zhang, Fang Jiang, Wenming Li. Effect of team-based intervention on blood glucose control effect and self-care ability in diabetic patients treated by insulin pump [J]. Journal of Qilu Nursing, 2021, 27 (21): 161-163.
[11]	Dequan Gui, Wentao Zhu, Na Zhang. Application Status and Existing Problems of cost-effectiveness Analysis in Pharmaceutical Economics Research. [J] China Pharmacy, 2009, 20 (11): 805-807.
[12]	Du Yaling. Analysis of hospitalization cost of intensive insulin therapy in patients with type 2 diabetes. [D] Shihezi University, 2014.
[13]	JieweiHuang, Yanping Li, Xiaohua Lu, et al. Construction of insulin pump application management path in patients with perioperative hyperglycemia. [J] Journal of Refrefresher Education, 2020, 35 (1): 1006-1009.
[14]	Maojuan He, Xiuxia Zhou. Perioperative nursing observation of neurosurgery patients with diabetes mellitus [J]. Diabetes New World, 2017, 20 (21): 124-125.
[15]	Yingmei Su. Perioperative care of 102 patients with diabetes [J]. Journal of Qiqihar Medical College, 2013, 34 (15): 2319-2320.
[16]	Mcmanus L M, Bloodworth R C, Prihoda T J, et al. Agonist-dependent failure of neutrophil function i diabetes correlates with extent of hyperglycemia [J]. Leukoc Biol. 2001, 70 (3): 395-404.
[17]	Chengli Liu, Cheng Wang, et al. Effect of immune nutrients on the incidence of infection after malignant obstructive jaundice and biliary stenting. [J]. Progress in Modern Biomedical Sciences, 2017, 17 (05): 882-885.
[18]	The Ministry of the People's Health of China. Diagnosis criteria for nosocomial infection (trial) [J]. Chinese Medical Journal, 2001, (05): 61-67.
[19]	Roze S, Smith-Palmer J, Delbaere A, et al. cost-effectiveness of Continuous Subcutaneous Insulin Infusion Versus Multiple Daily Injections in Patients with Poorly Controlled Type 2 Diabetes in Finland. [J]. Diabetes Therapy, 2019, 10 (2): 563-574.
[20]	Wei Yang, Linlang Liang, Ping Li, et al. Analysis of the cost and benefit of intensive insulin pump therapy in hospitalized diabetes [J]. Shenyang Army Medicine 2010, 23 (01): 49-51.

Cite This Article

Plain Text BibTeX RIS

APA Style

Na Li, Jiewei Huang, Peiru Zhou, Xueyan Liu, Xiaohua Lu, et al. (2022). Cost-Effectiveness Analysis of Insulin Pump Therapy for Patients with Type 2 Diabetes Mellitus in the Perioperative Period. International Journal of Diabetes and Endocrinology, 7(3), 70-76. https://doi.org/10.11648/j.ijde.20220703.15

Copy | Download

ACS Style

Na Li; Jiewei Huang; Peiru Zhou; Xueyan Liu; Xiaohua Lu, et al. Cost-Effectiveness Analysis of Insulin Pump Therapy for Patients with Type 2 Diabetes Mellitus in the Perioperative Period. Int. J. Diabetes Endocrinol. 2022, 7(3), 70-76. doi: 10.11648/j.ijde.20220703.15

Copy | Download

AMA Style

Na Li, Jiewei Huang, Peiru Zhou, Xueyan Liu, Xiaohua Lu, et al. Cost-Effectiveness Analysis of Insulin Pump Therapy for Patients with Type 2 Diabetes Mellitus in the Perioperative Period. Int J Diabetes Endocrinol. 2022;7(3):70-76. doi: 10.11648/j.ijde.20220703.15

Copy | Download

@article{10.11648/j.ijde.20220703.15,
  author = {Na Li and Jiewei Huang and Peiru Zhou and Xueyan Liu and Xiaohua Lu and Qingling Chen and Yan Zhou},
  title = {Cost-Effectiveness Analysis of Insulin Pump Therapy for Patients with Type 2 Diabetes Mellitus in the Perioperative Period},
  journal = {International Journal of Diabetes and Endocrinology},
  volume = {7},
  number = {3},
  pages = {70-76},
  doi = {10.11648/j.ijde.20220703.15},
  url = {https://doi.org/10.11648/j.ijde.20220703.15},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ijde.20220703.15},
  abstract = {Objective: In recent years, insulin pump, as one of the effective glycemic control therapy in perioperative hyperglycemia patients, has been gradually applied and promoted in clinical type 2 diabetes patients, but there is a contradictory statements of whther it is ecomonical. To analyze the cost and effect of perioperative insulin pump treatment in patients with type 2 diabetes, this artical compared the cost-effectiveness of glucose control in the perioperative insulin pump treatment group (CSII group) with multiple daily subcutaneous insulin treatment group (MDI group) and subcutaneous insulin + oral hypoglycemic drug treatment group (subcutaneous + oral treatment group). Methods: This study is based on the cost-effectiveness analysis method, compared the difference in glucose-control treatment costs and treatment effect of the three perioperative glucose control schemes, and conducted the sensitivity analysis of the corresponding indicators. Results: The comparison of the basic data between the three patient groups was not significantly significant (P > 0.05), and it was comparable. The fastest in CSII was (3.52 ± 2.94) days, and the incidence of postoperative infection in CSII patients was basically the same as that in the subcutaneous + oral treatment group, with 12.9% and 12.5%, respectively. The savings in CSII, MDI and subcutaneous + oral treatment by 1d were 609.07, 343.83 and 311.25, respectively, much more in CSII than MDI and subcutaneous + oral treatment; reducing the postoperative infection rate by 1 percentage point was 166.20, 60.34 and 135.70, respectively, in CSII than MDI and subcutaneous + oral treatment. Comprehensive analysis shows that CSII has a good cost-effectiveness. The results of sensitivity analysis showed the credibility and stability of this study. Conclusions: Insulin pump treatment in perioperative type 2 diabetes patients is a cost-effectiveness treatment scheme, and it is very useful in perioperative type 2 diabetes patients.},
 year = {2022}
}

Copy | Download

TY  - JOUR
T1  - Cost-Effectiveness Analysis of Insulin Pump Therapy for Patients with Type 2 Diabetes Mellitus in the Perioperative Period
AU  - Na Li
AU  - Jiewei Huang
AU  - Peiru Zhou
AU  - Xueyan Liu
AU  - Xiaohua Lu
AU  - Qingling Chen
AU  - Yan Zhou
Y1  - 2022/08/27
PY  - 2022
N1  - https://doi.org/10.11648/j.ijde.20220703.15
DO  - 10.11648/j.ijde.20220703.15
T2  - International Journal of Diabetes and Endocrinology
JF  - International Journal of Diabetes and Endocrinology
JO  - International Journal of Diabetes and Endocrinology
SP  - 70
EP  - 76
PB  - Science Publishing Group
SN  - 2640-1371
UR  - https://doi.org/10.11648/j.ijde.20220703.15
AB  - Objective: In recent years, insulin pump, as one of the effective glycemic control therapy in perioperative hyperglycemia patients, has been gradually applied and promoted in clinical type 2 diabetes patients, but there is a contradictory statements of whther it is ecomonical. To analyze the cost and effect of perioperative insulin pump treatment in patients with type 2 diabetes, this artical compared the cost-effectiveness of glucose control in the perioperative insulin pump treatment group (CSII group) with multiple daily subcutaneous insulin treatment group (MDI group) and subcutaneous insulin + oral hypoglycemic drug treatment group (subcutaneous + oral treatment group). Methods: This study is based on the cost-effectiveness analysis method, compared the difference in glucose-control treatment costs and treatment effect of the three perioperative glucose control schemes, and conducted the sensitivity analysis of the corresponding indicators. Results: The comparison of the basic data between the three patient groups was not significantly significant (P > 0.05), and it was comparable. The fastest in CSII was (3.52 ± 2.94) days, and the incidence of postoperative infection in CSII patients was basically the same as that in the subcutaneous + oral treatment group, with 12.9% and 12.5%, respectively. The savings in CSII, MDI and subcutaneous + oral treatment by 1d were 609.07, 343.83 and 311.25, respectively, much more in CSII than MDI and subcutaneous + oral treatment; reducing the postoperative infection rate by 1 percentage point was 166.20, 60.34 and 135.70, respectively, in CSII than MDI and subcutaneous + oral treatment. Comprehensive analysis shows that CSII has a good cost-effectiveness. The results of sensitivity analysis showed the credibility and stability of this study. Conclusions: Insulin pump treatment in perioperative type 2 diabetes patients is a cost-effectiveness treatment scheme, and it is very useful in perioperative type 2 diabetes patients.
VL  - 7
IS  - 3
ER  -

Copy | Download

Author Information

Na Li

Central Operating Room, the First Affiliated Hospital of Jinan University, Guangzhou, China
Jiewei Huang

Central Operating Room, the First Affiliated Hospital of Jinan University, Guangzhou, China
Peiru Zhou

Central Operating Room, the First Affiliated Hospital of Jinan University, Guangzhou, China
Xueyan Liu

Department of Endocrinology and Metabolism, the First Affiliated Hospital of Jinan University, Guangzhou, China
Xiaohua Lu

Department of Endocrinology and Metabolism, the First Affiliated Hospital of Jinan University, Guangzhou, China
Qingling Chen

Department of Endocrinology and Metabolism, the First Affiliated Hospital of Jinan University, Guangzhou, China
Yan Zhou

Department of Endocrinology and Metabolism, the First Affiliated Hospital of Jinan University, Guangzhou, China

Download PDF

Sections

Plain Text BibTeX RIS

APA Style

Na Li, Jiewei Huang, Peiru Zhou, Xueyan Liu, Xiaohua Lu, et al. (2022). Cost-Effectiveness Analysis of Insulin Pump Therapy for Patients with Type 2 Diabetes Mellitus in the Perioperative Period. International Journal of Diabetes and Endocrinology, 7(3), 70-76. https://doi.org/10.11648/j.ijde.20220703.15

Copy | Download

ACS Style

Na Li; Jiewei Huang; Peiru Zhou; Xueyan Liu; Xiaohua Lu, et al. Cost-Effectiveness Analysis of Insulin Pump Therapy for Patients with Type 2 Diabetes Mellitus in the Perioperative Period. Int. J. Diabetes Endocrinol. 2022, 7(3), 70-76. doi: 10.11648/j.ijde.20220703.15

Copy | Download

AMA Style

Na Li, Jiewei Huang, Peiru Zhou, Xueyan Liu, Xiaohua Lu, et al. Cost-Effectiveness Analysis of Insulin Pump Therapy for Patients with Type 2 Diabetes Mellitus in the Perioperative Period. Int J Diabetes Endocrinol. 2022;7(3):70-76. doi: 10.11648/j.ijde.20220703.15

Copy | Download

@article{10.11648/j.ijde.20220703.15,
  author = {Na Li and Jiewei Huang and Peiru Zhou and Xueyan Liu and Xiaohua Lu and Qingling Chen and Yan Zhou},
  title = {Cost-Effectiveness Analysis of Insulin Pump Therapy for Patients with Type 2 Diabetes Mellitus in the Perioperative Period},
  journal = {International Journal of Diabetes and Endocrinology},
  volume = {7},
  number = {3},
  pages = {70-76},
  doi = {10.11648/j.ijde.20220703.15},
  url = {https://doi.org/10.11648/j.ijde.20220703.15},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ijde.20220703.15},
  abstract = {Objective: In recent years, insulin pump, as one of the effective glycemic control therapy in perioperative hyperglycemia patients, has been gradually applied and promoted in clinical type 2 diabetes patients, but there is a contradictory statements of whther it is ecomonical. To analyze the cost and effect of perioperative insulin pump treatment in patients with type 2 diabetes, this artical compared the cost-effectiveness of glucose control in the perioperative insulin pump treatment group (CSII group) with multiple daily subcutaneous insulin treatment group (MDI group) and subcutaneous insulin + oral hypoglycemic drug treatment group (subcutaneous + oral treatment group). Methods: This study is based on the cost-effectiveness analysis method, compared the difference in glucose-control treatment costs and treatment effect of the three perioperative glucose control schemes, and conducted the sensitivity analysis of the corresponding indicators. Results: The comparison of the basic data between the three patient groups was not significantly significant (P > 0.05), and it was comparable. The fastest in CSII was (3.52 ± 2.94) days, and the incidence of postoperative infection in CSII patients was basically the same as that in the subcutaneous + oral treatment group, with 12.9% and 12.5%, respectively. The savings in CSII, MDI and subcutaneous + oral treatment by 1d were 609.07, 343.83 and 311.25, respectively, much more in CSII than MDI and subcutaneous + oral treatment; reducing the postoperative infection rate by 1 percentage point was 166.20, 60.34 and 135.70, respectively, in CSII than MDI and subcutaneous + oral treatment. Comprehensive analysis shows that CSII has a good cost-effectiveness. The results of sensitivity analysis showed the credibility and stability of this study. Conclusions: Insulin pump treatment in perioperative type 2 diabetes patients is a cost-effectiveness treatment scheme, and it is very useful in perioperative type 2 diabetes patients.},
 year = {2022}
}

Copy | Download

TY  - JOUR
T1  - Cost-Effectiveness Analysis of Insulin Pump Therapy for Patients with Type 2 Diabetes Mellitus in the Perioperative Period
AU  - Na Li
AU  - Jiewei Huang
AU  - Peiru Zhou
AU  - Xueyan Liu
AU  - Xiaohua Lu
AU  - Qingling Chen
AU  - Yan Zhou
Y1  - 2022/08/27
PY  - 2022
N1  - https://doi.org/10.11648/j.ijde.20220703.15
DO  - 10.11648/j.ijde.20220703.15
T2  - International Journal of Diabetes and Endocrinology
JF  - International Journal of Diabetes and Endocrinology
JO  - International Journal of Diabetes and Endocrinology
SP  - 70
EP  - 76
PB  - Science Publishing Group
SN  - 2640-1371
UR  - https://doi.org/10.11648/j.ijde.20220703.15
AB  - Objective: In recent years, insulin pump, as one of the effective glycemic control therapy in perioperative hyperglycemia patients, has been gradually applied and promoted in clinical type 2 diabetes patients, but there is a contradictory statements of whther it is ecomonical. To analyze the cost and effect of perioperative insulin pump treatment in patients with type 2 diabetes, this artical compared the cost-effectiveness of glucose control in the perioperative insulin pump treatment group (CSII group) with multiple daily subcutaneous insulin treatment group (MDI group) and subcutaneous insulin + oral hypoglycemic drug treatment group (subcutaneous + oral treatment group). Methods: This study is based on the cost-effectiveness analysis method, compared the difference in glucose-control treatment costs and treatment effect of the three perioperative glucose control schemes, and conducted the sensitivity analysis of the corresponding indicators. Results: The comparison of the basic data between the three patient groups was not significantly significant (P > 0.05), and it was comparable. The fastest in CSII was (3.52 ± 2.94) days, and the incidence of postoperative infection in CSII patients was basically the same as that in the subcutaneous + oral treatment group, with 12.9% and 12.5%, respectively. The savings in CSII, MDI and subcutaneous + oral treatment by 1d were 609.07, 343.83 and 311.25, respectively, much more in CSII than MDI and subcutaneous + oral treatment; reducing the postoperative infection rate by 1 percentage point was 166.20, 60.34 and 135.70, respectively, in CSII than MDI and subcutaneous + oral treatment. Comprehensive analysis shows that CSII has a good cost-effectiveness. The results of sensitivity analysis showed the credibility and stability of this study. Conclusions: Insulin pump treatment in perioperative type 2 diabetes patients is a cost-effectiveness treatment scheme, and it is very useful in perioperative type 2 diabetes patients.
VL  - 7
IS  - 3
ER  -

Copy | Download